VYNE earnings

Following closing, combined company plans to progress Yarrow's lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor ("TSHR") antibody for Graves' disease ("GD") and thyroid eye disease ("TED")Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd ("GenSci")Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028Companies to

BRIDGEWATER, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that its Board of Directors has approved a reverse stock split of the Company's common stock at a ratio of 1-for-18. The reverse stock split was previously approved by stockholders at the Special Meeting of Stockholders on January 12, 2023. The reverse stock split will become effective after market close on Friday, February 10, 2023 and shares will begin trading on a split-adjusted basis when the market opens on Mo

Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate Atopic Dermatitis Expected Early Q1 2022 Process for Sale of Topical Minocycline Franchise Continues to Advance Conference call and Live Webcast Today at 8:30 am Eastern Time BRIDGEWATER, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "The third quarter marks an important turning point for VYNE, as our company is now fully enga

BRIDGEWATER, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that it will report its financial results for the third quarter ended September 30, 2021, on Wednesday, November 10, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details:Wednesday, November 10th @ 8:30am Eastern TimeToll Free:855-327-6837International:631-891-4304Conference ID:10017178Webcast:https://themediaframe.com/mediaframe/webcast.html?webcastid=44cKOFEX A replay of the call will be archived on the Company's website at

Company announced license agreement with In4Derm Limited for BETi platform earlier this morning Company has initiated a process to explore a sale or license of its topical minocycline franchise Phase 2a results for FMX114 expected by year end and VYN201 and VYN202 to enter the clinic in 2022 Company has prepaid the entirety of its outstanding debt and expects to significantly reduce operating expenses Conference call and live webcast today at 8:30 am Eastern Time BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced financial results for the second quarter ended June 30, 2021. The Company also announced that

VYNE will have exclusive access to a library of new chemical entities VYNE will prioritize initial development efforts on rare skin diseases and major immunology and inflammatory conditions with high unmet needs VYNE expects to enter VYN201 and VYN202 into the clinic in 2022 Further details will be discussed on VYNE's second quarter earnings call this morning at 8:30am EDT BRIDGEWATER, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that it has entered into an exclusive license agreement (the "License Agreement") with In4Derm Limited ("In4Derm"), a spin-out of the University of Dundee's School of Life Sciences focu

BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced that it will report its financial results for the second quarter ended June 30, 2021, on August 12, 2021, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call Details:Thursday, August 12th @ 8:30am Eastern Time Toll Free:877-256-3294International:212-231-2918Conference ID:21995997Webcast:http://public.viavid.com/index.php?id=145705 A replay of the call will be archived on the Company's website at www.vynetherapeutics.com after the confer